Market Research Report
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018
|Published by||FirstWord||Product code||593153|
Delivery time: 1-2 business days
|Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018|
|Published: April 1, 2018||Content info:||
Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out?
Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) .
Based on a survey of 150 European diabetologists from the leading EU5 markets (France, Germany, Italy, Spain, and the UK), the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Janssen Cilag, Merck Sharp & Dohme, and Takeda. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 9 Oral Type 2 Diabetes Mellitus Treatments
Exploring Market Access Barriers
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key issues affecting type 2 diabetes mellitus drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 diabetologists and primary care physicians-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between April 5-10, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.